Question explored with the scientific record
do statins work?
The short version: statins reduce cardiovascular events in people who already have disease, but the benefit for healthy people is small and the diabetes risk is real.
The evidence here is mostly about people with established disease or diabetes, not healthy people. In secondary prevention, statins cut major events by roughly 20 percent, with an absolute reduction around 4 percent over five years [17]. In primary prevention, the absolute reduction is about 1.5 percent [17]. That is the difference between 98.5 and 100 people avoiding an event. The diabetes risk is consistent: roughly a 20 percent relative increase in new-onset diabetes, which is about 0.5 percent absolute [4, 30, 31]. High-intensity statins carry more diabetes risk than moderate doses [12].
The funding picture is not clean. Most of these trials were industry-run, and the meta-analyses inherit that bias. The 2025 Korean cohort study is observational, not randomized, so it cannot prove causation [3]. The 2022 diabetes cohort is also observational [6]. No trial here compares statins against a true placebo over decades with hard all-cause mortality as the primary endpoint. The surrogate endpoint problem is real: many studies track LDL reduction or plaque regression, not death [7, 23].
| Population | Absolute event reduction | Diabetes risk increase |
|---|---|---|
| Secondary prevention | ~4.6% over 5 years [17] | ~0.5% absolute [30] |
| Primary prevention | ~1.5% over 5 years [17] | ~0.5% absolute [30] |
| High-intensity vs moderate | - | Higher NODM [12] |
The mechanism matters. Statins lower LDL, but the 2013 Circulation study found that on-treatment CRP, not LDL, predicted events [7]. That suggests the benefit may be anti-inflammatory, not purely cholesterol-driven. The 2025 Naples cohort found low LDL itself was associated with higher diabetes risk, independent of statins [32]. That complicates the simple "lower is better" story.
My call: statins are worth it for people with known heart disease or prior stroke. For healthy people, the benefit is small, the diabetes risk is real, and the evidence base is industry-funded and observational at the margins.
Sources used 32
-
CORONARY VASCULAR DYSFUNCTION IS ASSOCIATED WITH INCREASED EPICARDIAL ADIPOSE TISSUE AND MAJOR ADVERSE CARDIOVASCULAR EVENTS
This study investigates the relationship between impaired coronary artery distensibility index (CDI), increased epicardial adipose tissue (EAT), and the incidence of major adverse cardiovascular events (MACE) in a cohort of statin-therapy patients.
DOI: 10.1016/s0735-1097(12)62102-0 -
Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events
A critical synthesis of major omega-3 trials (notably REDUCE-IT vs STRENGTH) assessing whether EPA-only therapy (icosapent ethyl) reduces major adverse cardiovascular events, and discussing how drug formulation, dose, and placebo choice influence outcomes and implications for AS…
DOI: 10.1001/jama.2020.22387 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
Risk of New-Onset Diabetes Mellitus Versus Reduction in Cardiovascular Events With Statin Therapy
This study investigates the risk of new-onset diabetes mellitus (NODM) and the reduction of major adverse cardiovascular events (MACE) in prediabetic patients undergoing statin therapy, finding that while statins increase the risk of NODM, they significantly reduce MACE, suggest…
DOI: 10.1016/j.amjcard.2013.10.043 -
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
This systematic review and meta-analysis evaluates the efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease, finding significant improvements in lipid profiles and reductions in all-cause mortality and major adverse cardiovascul…
DOI: 10.1002/cpt.1859 -
Relative contributions of statin intensity, achieved low-density lipoprotein cholesterol level, and statin therapy duration to cardiovascular risk reduction in patients with type 2 diabetes: population based cohort study
In Korean patients with type 2 diabetes on statins, longer statin therapy duration was the strongest predictor of lower major adverse cardiovascular event risk, followed by achieved LDL-C level and statin intensity.
DOI: 10.1186/s12933-022-01466-z -
C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy
This study investigates the relationship between C-reactive protein (CRP) levels and coronary atheroma regression and cardiovascular events in patients undergoing maximally intensive statin therapy, finding that nonincreasing CRP levels are associated with greater atheroma regre…
DOI: 10.1161/CIRCULATIONAHA.113.004243 -
Impact of Statin Use on Outcomes After Coronary Artery Bypass Graft Surgery
This study investigates the impact of early statin therapy on clinical outcomes, demonstrating that initiating statin use within one month after coronary artery bypass graft (CABG) surgery significantly reduces the risk of all-cause mortality and major adverse cardiovascular eve…
DOI: 10.1161/circulationaha.108.799445 -
Fluvastatin in the first-line therapy of acute coronary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial)
A multicenter, randomized, double-blind, placebo-controlled trial in acute coronary syndrome showed that initiating fluvastatin 80 mg at hospital admission did not change inflammatory biomarkers (CRP, IL-6, PAPP-A) over 2–30 days but significantly reduced one-year major adverse …
DOI: 10.1186/1745-6215-11-61 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Standard-Dose Statin Therapy Provides Incremental Clinical Benefits in Normocholesterolemic Diabetic Patients
This study investigates the effects of standard-dose statin therapy on cardiovascular outcomes in normocholesterolemic diabetic patients, demonstrating significant clinical benefits compared to non-statin therapy.
DOI: 10.1253/circj.cj-09-0243 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Cardiovascular Risk Assessment and Hyperlipidemia
This article reviews the identification and risk stratification of patients at risk for coronary artery disease (CAD) and the management of their lipid levels, emphasizing the pivotal role of healthcare providers in treatment decisions.
DOI: 10.1016/j.ccell.2008.03.014 -
The pharmaco‐economics of peri‐operative statin therapy
This study analyzes the cost-effectiveness of peri-operative statin therapy in patients undergoing major elective vascular surgery, suggesting it may be the most cost-effective use of statins due to a favorable number-needed-to-treat of 15 for preventing adverse cardiovascular e…
DOI: 10.1111/j.1365-2044.2005.04371.x -
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
This study evaluates the cost-effectiveness of PCSK9 inhibitors in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease, finding that their use does not meet acceptable cost-effectiveness thresholds at 2015 prices and would significa…
DOI: 10.1001/jama.2016.11004 -
A peri‐operative statin update for non‐cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non‐surgical) patients
This review synthesizes evidence on statin therapy for peri-operative use, concluding that stable coronary artery disease patients require 4-6 weeks of therapy with LDL-C reduction as the key target, while patients experiencing acute coronary syndromes need early high-dose stati…
DOI: 10.1111/j.1365-2044.2007.05264.x -
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
This systematic review and meta-analysis evaluates the relationship between lowering low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk reduction across various therapeutic interventions, finding that both statins and nonstatin therapies that upregulate LDL rece…
DOI: 10.1001/jama.2016.13985 -
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
A comprehensive narrative review of how low-density lipoprotein cholesterol (LDL-C) relates to cardiovascular disease risk, evaluating evidence-based LDL-C lowering strategies (lifestyle, statins, non-statin drugs, and emerging therapies), comparing major guidelines, and discuss…
DOI: 10.1016/j.jacl.2015.11.010 -
THE MECHANISM OF LONG-TERM LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING EFFECT OF EZETIMIBE-PLUS-STATIN COMBINATION THERAPY IN CORONARY ARTERY DISEASE PATIENTS; COMPARED WITH DOUBLE-DOSE STATIN THERAPY
This study investigates the long-term effects of ezetimibe combined with statin therapy versus double-dose statin therapy on LDL-C levels in coronary artery disease patients, revealing that the combination therapy leads to greater and more stable LDL-C reduction over time.
DOI: 10.1016/S0735-1097(12)61542-3 -
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
A post-hoc pooled analysis of multiple evolocumab trials shows substantial LDL-C reduction in patients with mixed hyperlipidemia (elevated triglycerides) that is similar to those without elevated triglycerides, with concurrent improvements in non-HDL-C and ApoB and overall good …
DOI: 10.1007/s10557-016-6666-1 -
Efficacy/Role of Combination Therapy Versus Mono Therapy in Improving Triglycerides and Low Density Lipoprotein Cholesterol in Patients Uncontrolled on Monotherapy
Adding fenofibrate to ongoing statin therapy in patients with dyslipidemia uncontrolled on statin monotherapy significantly lowers triglycerides, total cholesterol, and raises HDL-C, but does not produce a significant LDL-C reduction after two months.
DOI: 10.63163/jpehss.v3i2.453 -
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
This study evaluates the impact of adding ezetimibe to statin therapy on LDL-C levels and goal attainment in high-risk coronary heart disease patients compared to titrating statin monotherapy, finding significant improvements in both LDL-C reduction and goal attainment with the …
DOI: 10.2147/VHRM.S49840 -
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
A comprehensive meta-analysis showing that adding ezetimibe or PCSK9 inhibitors to statin therapy significantly regresses coronary atherosclerosis measured by IVUS, with greater regression corresponding to larger reductions in LDL-C and non-HDL-C.
DOI: 10.1186/s12944-020-01297-5 -
A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia
This meta-analysis evaluates the impact of statin therapy on low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels in patients with hypertriglyceridaemia, revealing that rosuvastatin significantly outperforms atorvastatin and simvastatin in reducing both LDL-C…
DOI: 10.1016/j.amjcard.2016.02.011 -
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
A comprehensive meta-analysis of 29 randomized trials (266,148 patients) shows that baseline body mass index (BMI) modulates the cardiovascular benefit of intensive LDL-C lowering therapy, with the greatest reductions in cardiovascular and all-cause mortality observed in individ…
DOI: 10.1016/j.amjcard.2019.12.006 -
Switching to rosuvastatin plus ezetimibe in statin-treated stroke patients with low-density lipoprotein cholesterol levels above 70 mg/dL (SWITCH): a prospective observational study
A real-world, multicenter prospective study in Korean stroke patients on statins evaluated switching to a rosuvastatin plus ezetimibe combination therapy (REZ); about 71% achieved LDL-C < 70 mg/dL at six months with substantial LDL-C reductions and acceptable safety.
DOI: 10.1186/s12944-025-02781-6 -
Characterization of diabetes risk factors in patients prescribed chronic statin therapy
This study investigates the incidence of diabetes risk factors over time in patients prescribed chronic statin therapy, revealing that while some metabolic parameters improved, the overall incidence of diabetes risk factors remained consistent.
DOI: 10.1177/2040622314530460 -
Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)
This study investigates the relationship between exercise capacity and the risk of developing diabetes in patients undergoing statin therapy, finding that higher exercise capacity is associated with a lower risk of incident diabetes regardless of statin use.
DOI: 10.1016/j.amjcard.2017.05.048 -
Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
This review examines the association between statin therapy and the risk of new-onset diabetes, highlighting that while statins may increase diabetes risk, the cardiovascular benefits significantly outweigh this risk, particularly in individuals with pre-existing diabetes risk f…
DOI: 10.1007/s11886-024-02141-3 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Is statin‐induced diabetes clinically relevant? A comprehensive review of the literature
This 2013 comprehensive review synthesizes evidence from randomized trials and meta-analyses to evaluate whether statin therapy increases the risk of new-onset diabetes, its magnitude, potential mechanisms, and clinical implications, concluding a small increased risk that is gen…
DOI: 10.1111/dom.12254 -
A six-year longitudinal study identifies a statin-independent association between low LDL-cholesterol and risk of type 2 diabetes
A six-year population-based cohort study in Naples, Italy shows an inverse association between LDL-cholesterol levels and incident type 2 diabetes risk that is largely independent of statin use, with the strongest risk at very low LDL-C and a statin-associated increase in risk o…
DOI: 10.1186/s12933-025-02964-6